{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:26:45Z","timestamp":1761863205815,"version":"3.40.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.semcancer.2013.02.002","type":"journal-article","created":{"date-parts":[[2013,2,11]],"date-time":"2013-02-11T20:01:39Z","timestamp":1360612899000},"page":"183-189","source":"Crossref","is-referenced-by-count":35,"title":["PMN and anti-tumor immunity\u2014The case of bladder cancer immunotherapy"],"prefix":"10.1016","volume":"23","author":[{"given":"Erik L.","family":"Brincks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Risk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2013.02.002_bib0005","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0010","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0015","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1289\/ehp.94102590","article-title":"Priorities for future IARC monographs on the evaluation of carcinogenic risks to humans","volume":"102","author":"Vainio","year":"1994","journal-title":"Environmental Health Perspectives"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2004.03.017","article-title":"Non-invasive urothelial neoplasms: according to the most recent WHO classification","volume":"46","author":"Lopez-Beltran","year":"2004","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0035","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.juro.2007.01.055","article-title":"Bladder and upper tract urothelial cancer","volume":"177","author":"Konety","year":"2007","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.eururo.2010.01.025","article-title":"Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations","volume":"57","author":"Witjes","year":"2010","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0050","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.eururo.2011.05.053","article-title":"Urine markers for detection and surveillance of non-muscle-invasive bladder cancer","volume":"60","author":"Tilki","year":"2011","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0060","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eururo.2007.12.031","article-title":"Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"54","author":"Herr","year":"2008","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0070","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0075","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0974-7796.84954","article-title":"Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette\u2013Guerin","volume":"3","author":"Alkhateeb","year":"2011","journal-title":"Urology Annals"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0085","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000336516","article-title":"Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables","volume":"89","author":"Altieri","year":"2012","journal-title":"Urology International"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0090","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette\u2013Guerin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00345-010-0635-2","article-title":"External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer","volume":"29","author":"Hernandez","year":"2011","journal-title":"World Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0100","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1464-410X.2012.10996.x","article-title":"Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer","volume":"110","author":"van Rhijn","year":"2012","journal-title":"BJU International"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","article-title":"Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer","volume":"58","author":"van Rhijn","year":"2010","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0110","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0090-4295(97)00402-0","article-title":"Intralesional administration of biological response modifiers in the treatment of localized cancer of the prostate: a feasibility study","volume":"50","author":"Morales","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette\u2013Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU International"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0120","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette\u2013Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0130","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette\u2013Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0135","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette\u2013Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0145","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0150","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette\u2013Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0155","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette\u2013Guerin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU International"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0160","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette\u2013Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0165","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette\u2013Guerin (27mg) versus very low-dose bacillus Calmette\u2013Guerin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0170","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","article-title":"Fibronectin-mediated Calmette\u2013Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response","volume":"85","author":"Kavoussi","year":"1990","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/clin.1995.1031","article-title":"Role of the immune response in interstitial cystitis","volume":"74","author":"Ratliff","year":"1995","journal-title":"Clinical Immunology and Immunopathology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0185","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1128\/CDLI.3.6.761-768.1996","article-title":"A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein","volume":"3","author":"Luo","year":"1996","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0190","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette\u2013Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0195","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0022-5347(17)45142-1","article-title":"Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG","volume":"136","author":"Haaff","year":"1986","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0200","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0090-4295(90)80220-H","article-title":"Urinary cytokines following photodynamic therapy for bladder cancer. A preliminary report","volume":"36","author":"Nseyo","year":"1990","journal-title":"Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0205","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00326845","article-title":"Changes of th emucosal architecture and of urine cytology during BCG treatment","volume":"6","author":"Shapiro","year":"1988","journal-title":"World Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0210","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01741603","article-title":"Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette\u2013Guerin","volume":"33","author":"de Boer","year":"1991","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0220","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0225","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.1995.155","article-title":"Bacillus Calmette\u2013Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing","volume":"71","author":"Pryor","year":"1995","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0230","first-page":"3729","article-title":"Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette\u2013Guerin-activated killer cells","volume":"6","author":"Brandau","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0235","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000052497","article-title":"Activation of natural killer cells by Bacillus Calmette\u2013Guerin","volume":"39","author":"Brandau","year":"2001","journal-title":"European Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0240","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1128\/IAI.63.9.3381-3387.1995","article-title":"Susceptibility of beige mice to Mycobacterium avium: role of neutrophils","volume":"63","author":"Appelberg","year":"1995","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0245","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/156.6.985","article-title":"Capacity of human neutrophils to kill Mycobacterium tuberculosis","volume":"156","author":"Brown","year":"1987","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0250","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1128\/IAI.65.8.3451-3456.1997","article-title":"Role of epithelial interleukin-8 (IL-8) and neutrophil IL-8 receptor A in Escherichia coli-induced transuroepithelial neutrophil migration","volume":"65","author":"Godaly","year":"1997","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0255","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-5347(01)64210-1","article-title":"Interleukin-8 expression in the urine after bacillus Calmette\u2013Guerin therapy: a potential prognostic factor of tumor recurrence and progression","volume":"158","author":"Thalmann","year":"1997","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0260","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette\u2013Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0265","series-title":"Principles and practice of infectious disease","first-page":"93","article-title":"Granulocytic phagocytes","author":"Nauseef","year":"2005"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0270","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective Bacillus Calmette\u2013Guerin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0275","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-03-1327","article-title":"Neutrophil stimulation with Mycobacterium bovis bacillus Calmette\u2013Guerin (BCG) results in the release of functional soluble TRAIL\/Apo-2L","volume":"106","author":"Kemp","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0280","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette\u2013Guerin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0285","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000085934","article-title":"Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette\u2013Guerin treatment","volume":"75","author":"Mehmut","year":"2005","journal-title":"Urology International"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0290","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0295","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0300","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0305","first-page":"1362","article-title":"Direct stimulation of apoptotic signaling by soluble Apo2l\/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells","volume":"7","author":"Pollack","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0310","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.leu.2401501","article-title":"TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells","volume":"13","author":"Gazitt","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0315","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1525-0016(03)00203-X","article-title":"Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers","volume":"8","author":"Lin","year":"2003","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0320","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/sj.gt.3301810","article-title":"Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft","volume":"9","author":"Huang","year":"2002","journal-title":"Gene Therapy"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0325","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.mam.2009.12.002","article-title":"TRAILing death in cancer","volume":"31","author":"Mellier","year":"2010","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0330","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcb.22549","article-title":"TRAIL\/TRAIL-R in hematologic malignancies","volume":"110","author":"Testa","year":"2010","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0335","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2009.06.066","article-title":"TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies","volume":"625","author":"Holoch","year":"2009","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0340","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1196\/annals.1339.042","article-title":"The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumors to Apo2L\/TRAIL-mediated apoptosis","volume":"1059","author":"Ganten","year":"2005","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0345","first-page":"677","article-title":"Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells","volume":"25","author":"Komdeur","year":"2004","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0350","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1535-7163.MCT-05-0514","article-title":"Enhancement of Apo2L\/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin","volume":"5","author":"Tsai","year":"2006","journal-title":"Molecular Cancer Therapy"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0355","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1189\/jlb.1211623","article-title":"Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and FasL","volume":"92","author":"Jinesh","year":"2012","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0360","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4161\/cbt.10.9.13237","article-title":"Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells","volume":"10","author":"Metwalli","year":"2010","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10495-010-0535-3","article-title":"Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist","volume":"16","author":"Griffith","year":"2011","journal-title":"Apoptosis"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0370","doi-asserted-by":"crossref","first-page":"BR47","DOI":"10.12659\/MSM.882203","article-title":"Chlorin-based photodynamic therapy enhances the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in bladder cancer cells","volume":"18","author":"Szliszka","year":"2012","journal-title":"Medical Science Monitor"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0375","first-page":"365","article-title":"Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells","volume":"38","author":"Yano","year":"2011","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0380","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.juro.2009.05.005","article-title":"Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins","volume":"182","author":"White-Gilbertson","year":"2009","journal-title":"Journal of Urology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0385","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/0008-5472.CAN-06-1224","article-title":"Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression","volume":"67","author":"Shrader","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0390","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/0008-5472.CAN-05-3017","article-title":"Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells","volume":"66","author":"Earel","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0395","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.cgt.7700905","article-title":"In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL","volume":"13","author":"El-Zawahry","year":"2006","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0400","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1158\/0008-5472.CAN-04-3701","article-title":"Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells","volume":"65","author":"Lashinger","year":"2005","journal-title":"Cancer Research"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0405","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4049\/jimmunol.170.2.1027","article-title":"Acceleration of human neutrophil apoptosis by TRAIL","volume":"170","author":"Renshaw","year":"2003","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0410","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.0019-2805.2003.01794.x","article-title":"Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils","volume":"111","author":"Kamohara","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0415","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1182\/blood-2003-08-2806","article-title":"IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL\/Apo-2 ligand) displaying apoptotic activity on leukemic cells","volume":"103","author":"Tecchio","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0420","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1189\/jlb.1005558","article-title":"On the production of TNF-related apoptosis-inducing ligand (TRAIL\/Apo-2L) by human neutrophils","volume":"79","author":"Cassatella","year":"2006","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0425","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1189\/jlb.0805431","article-title":"Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL\/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators","volume":"79","author":"Cassatella","year":"2006","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0430","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.57.1.2","article-title":"Apoptosis in leukocytes","volume":"57","author":"Squier","year":"1995","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0435","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.micinf.2003.09.008","article-title":"Neutrophil granules and secretory vesicles in inflammation","volume":"5","author":"Faurschou","year":"2003","journal-title":"Microbes and Infection"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0440","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood.V89.10.3503","article-title":"Granules of the human neutrophilic polymorphonuclear leukocyte","volume":"89","author":"Borregaard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0445","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0026-895X(24)12311-5","article-title":"Up-regulation of p21(WAF1\/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity","volume":"60","author":"Burgess","year":"2001","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0450","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1189\/jlb.0707452","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules","volume":"83","author":"Simons","year":"2008","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0455","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/IAI.00938-06","article-title":"Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils","volume":"75","author":"Simons","year":"2007","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0460","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/1097-0215(20000915)87:6<844::AID-IJC14>3.0.CO;2-5","article-title":"What are the immunologically active components of bacille Calmette\u2013Guerin in therapy of superficial bladder cancer?","volume":"87","author":"Zlotta","year":"2000","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0465","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/13543784.17.7.1067","article-title":"Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent","volume":"17","author":"Morales","year":"2008","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0470","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1074\/jbc.274.8.4521","article-title":"Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP","volume":"274","author":"Zhao","year":"1999","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0475","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.cgt.7700865","article-title":"Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation","volume":"13","author":"Tao","year":"2006","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0480","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","article-title":"Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein","volume":"10","author":"Benedict","year":"2004","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0485","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1158\/0008-5472.CAN-04-1909","article-title":"Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells","volume":"64","author":"Papageorgiou","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0490","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1084\/jem.20120983","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice","volume":"209","author":"Steinwede","year":"2012","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0495","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.4049\/jimmunol.181.7.4918","article-title":"CD8 T cells utilize TRAIL to control influenza virus infection","volume":"181","author":"Brincks","year":"2008","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0500","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2009-04-217927","article-title":"Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients","volume":"114","author":"Stary","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0505","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.humimm.2008.07.012","article-title":"Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells","volume":"69","author":"Brincks","year":"2008","journal-title":"Human Immunology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0510","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.4049\/jimmunol.1002241","article-title":"The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL","volume":"187","author":"Brincks","year":"2011","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0515","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1189\/jlb.0211062","article-title":"TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation","volume":"90","author":"McGrath","year":"2011","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0520","doi-asserted-by":"crossref","first-page":"e18291","DOI":"10.1371\/journal.pone.0018291","article-title":"HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species","volume":"6","author":"Zhu","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0525","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1084\/jem.20112716","article-title":"Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension","volume":"209","author":"Hameed","year":"2012","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.semcancer.2013.02.002_bib0530","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ccr.2012.05.014","article-title":"Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth","volume":"22","author":"Wilson","year":"2012","journal-title":"Cancer Cell"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X1300014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X1300014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:39:21Z","timestamp":1745959161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X1300014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1044579X1300014X"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2013.02.002","relation":{},"ISSN":["1044-579X"],"issn-type":[{"type":"print","value":"1044-579X"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}